Onkos Surgical's 510(k)-Cleared My3D Patient-Specific Pelvic Implant Platform Crosses 1,000 Surgical Cases

Onkos Surgical, a Parsippany, New Jersey-based orthopedic oncology company, has completed the 1,000th surgical case using its 510(k)-cleared My3D pelvic implant platform. Each My3D implant is 3D printed to match an individual patient's anatomy rather than chosen from a fixed catalogue of sizes, addressing pelvic reconstructions complicated by tumor resection, bone loss, or prior revision surgery. The workflow bundles imaging, 3D anatomic modeling, surgeon planning, and patient-specific implant design into one process; Onkos says it delivers on competitive lead times and pricing rather than as a premium niche product. CEO Patrick Treacy called the milestone significant for the company and the surgeons it partners with on complex reconstructions.

Patient-specific implants have been technically feasible for roughly a decade, but adoption has trailed surgical need whenever lead time or cost pushed surgeons back toward adapting an off-the-shelf component to the defect instead of the reverse. Reaching four figures of cases suggests My3D has moved past pilot-scale use into a repeatable service line in orthopedic oncology reconstruction, a niche where standard implants often cannot fit the anatomy at all. AMPulse's index lists Onkos, founded in 2015, as a growth-stage applications company with 21 linked active patent records, though the linkage is name-matched and likely undercounts related filings.